March 28th 2023
Patients with resistant or refractory ovarian cancer experience clinical benefits after receiving botensilimab plus balstilimab in the phase 1 C-800 study.
Leukemia Therapy – A Look Into the Future
View More
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Gastrointestinal Malignancies from Paris
View More
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
View More
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Community Practice Connections™: 4th annual Precision Medicine Symposium: An Illustrated Tumor Board
View More
Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic
View More
41st Annual Miami Breast Cancer Conference®
View More
From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis
View More
Medical Crossfire®: How Does the Evidence Inform Your RCC Sequence? The Experts Share Clinical Perspectives
View More
Oncology On-Call®: The Experts’ Take on How Sea Changes in GvHD Prophylaxis and Management Can Be Practically Implemented in Your Clinic
View More
Oncology On-Call®: The Experts’ Take on How Sea Changes in GvHD Prophylaxis and Management Can Be Practically Implemented in Your Clinic
View More
Community Practice Connections™: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Community Practice Connections™: MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
Community Practice Connections™: State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in GvHD Prevention and Treatment
View More
Clinical Vignettes: Inaugural International Congress on Pediatric Oncology
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
Community Practice Connections™: Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings
View More
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
10/13/2023-10/14/2023
View More
Keeping Pace with Rapid Advancements in Multiple Myeloma Care
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
22nd Annual International Congress on the Future of Breast Cancer® West
07/28/2023 - 07/29/2023
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Oncology Consultations®: Determining Treatment-Related Adverse Events from Disease Progression Along the MPN Care Continuum
View More
Trekking Through the Latest Updates for ROS1-Targeted Therapies
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
View More
Limited Efficacy, Manageable Safety Profile Found With TAS-117 to Treat Ovarian and Breast Cancer
April 11th 2021TAS-117 showed limited clinical efficacy in treating patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.
Secondary Cytoreduction Followed by Chemotherapy May Improve PFS in Ovarian Cancer
April 9th 2021The phase 3 SOC-1 trial found an association between secondary cytoreduction followed by chemotherapy and prolonged progression-free survival when compared with chemotherapy alone for patients with relapsed ovarian cancer.
Long-Term OS Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful Boost
April 5th 2021With more than 5 years of follow-up, results from the SOLO2 trial of olaparib maintenance in relapsed, high-grade serous or endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer, were reported and showed superiority of the agent over placebo.
ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer
March 20th 2021An update from the phase 3 ARIEL4 trial presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer supports the continued use of rucaparib in patients with BRCA-mutant relapsed advanced ovarian cancer, based on progression-free survival and response data.